In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...
Teva Pharmaceutical Indus 30-Day Option Volume & Interest Snapshot Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its ...
Teva and NICE Systems lost ground as the banks rose. The Tel Aviv Stock Exchange fell today. The Tel Aviv 35 Index fell 0.67%, to 2,491.34 points, the Tel Aviv 125 Index fell 0.37% to 2,564.04 points; ...
Teva Pharmaceutical Industries Limited has a 12-month low of $11.83 and a 12-month high of $22.80. The stock has a market capitalization of $19.07 billion, a PE ratio of -11.61, a price-to ...
Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 on Wednesday. The company lost over 20% in the preceding six sessions.
A spokesperson for the European Federation of Pharmaceutical Industries and Associations (EFPIA) declined to comment in an email to Pharmaceutical Technology on the US tariffs “as it would be ...
Teva Pharma Industries Ltd ADR (NYSE:TEVA) is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also has a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results